Defense Pharmaceuticals

Defence Therapeutics is a Canadian biotechnology company focused on enhancing the efficacy and safety of cancer treatments and vaccines through its proprietary Accum platform. The Accum technology is designed to improve the intracellular delivery of biological drugs, such as antibody-drug conjugates (ADCs) and mRNA vaccines, by facilitating their escape from endosomes into the cytoplasm. The company's pipeline includes several programs in oncology and infectious diseases, with its lead candidates, the ARM-002 vaccine and AccuTOX, advancing toward or entering Phase 1 clinical trials. Defence Therapeutics operates on a de-risked licensing model, seeking to partner its platform with major pharmaceutical companies to optimize their existing and next-generation therapeutic assets.